Michael J. Mauro
Impact in
- Hematology top 0.1%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Genetics top 0.2%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 210
- Chronic Myeloid Leukemia Treatments 203
- Acute Myeloid Leukemia Research 14
- Genetics 141
- Chronic Lymphocytic Leukemia Research 124
- Myeloproliferative Neoplasms: Diagnosis and Treatment 18
- Co-authors
- Brian J. Druker (29 shared papers)Jörge E. Cortes (72 shared papers)Michael W. Deininger (46 shared papers)Michael E O'Dwyer (7 shared papers)Andreas Hochhaus (33 shared papers)Hagop Kantarjian (20 shared papers)Moshe Talpaz (21 shared papers)Richard Thomas Maziarz (5 shared papers)
- Journals
- Blood (75 papers)Leukemia (19 papers)American Journal of Hematology (10 papers)Hematology (6 papers)Haematologica (6 papers)
- Partner nations
- United StatesGermanyFrance
In The Last Decade
Michael J. Mauro
219 papers receiving 7.7k citations
Michael J. Mauro's Hit Papers
Peers
Comparison fields: 5 of 107
- Hematology 5.5k
- Genetics 3.5k
- Rheumatology 2.1k
- Oncology 1.2k
- Cardiology and Cardiovascular Medicine 747
Countries citing papers authored by Michael J. Mauro
This map shows the geographic impact of Michael J. Mauro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Mauro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Mauro more than expected).
Fields of papers citing papers by Michael J. Mauro
This network shows the impact of papers produced by Michael J. Mauro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Mauro. The network helps show where Michael J. Mauro may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael J. Mauro, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 224 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias Hit paper breakdown → | 2012 | 622 |
| 2 | Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society Hit paper breakdown → | 2020 | 573 |
| 3 | Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial Hit paper breakdown → | 2017 | 383 |
| 4 | 2016 | 368 | |
| 5 | Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure Hit paper breakdown → | 2019 | 365 |
| 6 | A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs Hit paper breakdown → | 2021 | 238 |
| 7 | 2013 | 190 | |
| 8 | 2001 | 170 | |
| 9 | 2021 | 152 | |
| 10 | 2019 | 118 | |
| 11 | 2003 | 115 | |
| 12 | 2002 | 112 | |
| 13 | 2019 | 111 | |
| 14 | 2009 | 108 | |
| 15 | 2022 | 107 | |
| 16 | 2006 | 106 | |
| 17 | 2015 | 105 | |
| 18 | Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL Hit paper breakdown → | 2023 | 103 |
| 19 | 2007 | 100 | |
| 20 | 2003 | 96 |
About Michael J. Mauro
Michael J. Mauro is a scholar working on Hematology, Genetics, Rheumatology, Public Health, Environmental and Occupational Health and Organic Chemistry, having authored 224 papers that have together received 7.9k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (203 papers), Chronic Lymphocytic Leukemia Research (124 papers), Eosinophilic Disorders and Syndromes (83 papers), Acute Lymphoblastic Leukemia research (32 papers), Click Chemistry and Applications (28 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (18 papers), Acute Myeloid Leukemia Research (14 papers) and Mast cells and histamine (11 papers). The work is most often cited by research in Hematology (5.5k citations), Genetics (3.5k citations), Rheumatology (2.1k citations), Oncology (1.2k citations) and Cardiology and Cardiovascular Medicine (747 citations). Michael J. Mauro has collaborated with scholars based in United States, Germany and France. Frequent co-authors include Brian J. Druker, Jörge E. Cortes, Michael W. Deininger, Michael E O'Dwyer, Andreas Hochhaus, Hagop Kantarjian, Moshe Talpaz, Richard Thomas Maziarz, Richard D. Press and Frank G. Haluska. Their work appears in journals such as Blood, Leukemia, American Journal of Hematology, Hematology and Haematologica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.